Former Eli Lilly sales rep files Texas lawsuit alleging retaliation over Mounjaro off-label marketing complaint
A former Eli Lilly sales rep has sued, claiming retaliation after she objected to alleged off-label promotion of Mounjaro for weight loss. The case matters because it tests compliance and whistleblower protections in the fast-growing GLP-1 market, where demand can outpace approved indications. It remains an unproven allegation unless supported by evidence in litigation or regulatory action.
Jennifer Mansion, hired four years ago as a senior territory manager in Dallas, filed a lawsuit in federal court in Texas alleging she was fired after complaining that Eli Lilly sales representatives promoted Mounjaro for weight loss before FDA approval. The complaint says she observed other reps presenting the diabetes drug as a treatment for obesity and says a physician promoted it that way at a company-sponsored luncheon. The allegations are unproven.
The case rests on Mansion’s account and whatever documents, messages, or witness statements emerge in litigation. Off-label promotion means marketing a medicine for an indication not approved by regulators; physicians may prescribe off-label, but manufacturers may not. Mounjaro, tirzepatide, was approved for type 2 diabetes, while Eli Lilly later received approval for a separate weight-loss indication. The suit does not allege a clinical harm to patients, and the court has not found misconduct.
The claim matters because GLP-1 drugs are among the fastest-growing prescription markets, and demand for weight loss can outpace formal indications. If internal sales incentives rewarded early obesity promotion, regulators and investors would care about compliance controls, not just product demand. The case also tests whistleblower protections: companies often face higher reputational and legal risk when employees report suspected violations and then allege retaliation. It does not by itself establish a pattern.
Next, Eli Lilly is expected to respond in court, potentially challenging the claims or seeking dismissal. Discovery could reveal whether complaints were logged, how sales calls were documented, and whether physicians were paid to speak. For public health readers, the evidence is preliminary: a lawsuit is an allegation, not a study or regulatory finding. The next meaningful signal would be a docketed ruling, settlement, or FDA action citing specific promotional materials.
Sources (1)
- [1]Original source(https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/?utm_campaign=rss)